Monday 19 October 2026 / Guangzhou Haibote Pharmaceutical Technology
Guangzhou Haibote Pharmaceutical Technology
广州海博特医药科技有限公司
Haibote is a clinical trial contract research organisation (CRO) serving traditional Chinese medicine, small-molecule drug and biologics companies.
Guangzhou, ChinaBiotech & pharma
$10.5M
Series B, 19 October (7000万元)
Lead investorYuanyi Investment
Other investorsGuangyao Capital, Guangzhou Health Industry Investment, Guangzhou Jinkong, Jingxi Investment, Liwan Guangyao Fund, Wanlian Guangsheng
Reported by2 sources
What makes it different
The company has a team of over 500 staff, has taken on more than 1,250 clinical trials and works with over 600 pharmaceutical companies.
Haibote is a clinical trial contract research organisation (CRO) serving traditional Chinese medicine, small-molecule drug and biologics companies.
Founders
No founders were named in the reports of this round.
Funding history
Monday 19 October 2026
$10.5M Series B, led by Yuanyi Investment